Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 1 of 1 entries
View as:
Phase: N/A
Priority: Normal
Start: 10/31/17
End: 04/30/19
Due: 04/30/20
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Apatinib Plus Etoposide Versus Etoposide Alone for Platinum-resistant Recurrent Ovarian Cancer | NCT03298074 | Yang Zhijun | user2@example.com | None | 2017-10-31 | 2019-04-30 | 2020-04-30 | - | - | 2025-07-14 |